Recurrent head and neck cancer – pro
The recent UK guideline says that triple therapy with platinum, cetuximab and 5-fluorouracil (5-FU) appears to provide the best outcomes for the management of patients with recurrence who have a good performance status and are fit to receive it. If not fit, then combinations of platinum and cetuximab or platinum and 5-FU may be considered.
NCCN does not list this particular combination for recurrent disease on CHEM-A, 2, but lists singel agents or combinations without docetaxel.
H Mehanna et al, Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May; 130(Suppl 2): S181S190.
nccn.org, head and neck cancer, 2017
SS Agarwala et al, Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer Ann Oncol (2007) 18 (7): 1224-1229
MICHELLE L. MIERZWA, MUKESH K. NYATI, MEREDITH A. MORGAN, THEODORE S. LAWRENCE, Recent Advances in Combined Modality Therapy The Oncologist April 2010 vol. 15 no. 4 372-381